

# Chris Fegan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2243577/publications.pdf>

Version: 2024-02-01

84  
papers

3,492  
citations

218592  
26  
h-index

161767  
54  
g-index

85  
all docs

85  
docs citations

85  
times ranked

6432  
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016, 127, 411-419.	0.6	231
2	Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. <i>Leukemia</i> , 2015, 29, 1602-1604.	3.3	214
3	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. <i>Blood</i> , 2008, 112, 3807-3817.	0.6	208
4	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729.	0.8	197
5	Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. <i>Blood</i> , 2010, 116, 1899-1907.	0.6	148
6	The NF- $\kappa$ B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. <i>Blood</i> , 2008, 111, 4681-4689.	0.6	145
7	Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. <i>Nature Genetics</i> , 2013, 45, 1221-1225.	9.4	143
8	Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression. <i>Clinical Cancer Research</i> , 2012, 18, 678-687.	3.2	127
9	Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 541-564.	1.2	127
10	Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. <i>Function</i> , 2020, 1, zqaa002.	1.1	118
11	Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF- $\kappa$ B Activation and <i>De novo</i> Gene Transcription. <i>Cancer Research</i> , 2010, 70, 7523-7533.	0.4	88
12	Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. <i>Leukemia</i> , 1995, 9, 2003-8.	3.3	83
13	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. <i>British Journal of Haematology</i> , 2014, 167, 214-223.	1.2	73
14	Common Polymorphism G(-248)A in the Promoter Region of the bax Gene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is Initiated. <i>Journal of Clinical Oncology</i> , 2005, 23, 1514-1521.	0.8	69
15	The gut mucosal barrier in bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1990, 5, 373-7.	1.3	62
16	Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 763-769.	0.8	51
17	The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. <i>Blood</i> , 2010, 116, 2968-2974.	0.6	49
18	Highly purified CD38+ and CD38 $\alpha^{\sim}$ sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. <i>Leukemia</i> , 2007, 21, 687-696.	3.3	48

#	ARTICLE	IF	CITATIONS
19	Long-term follow-up of patients with CLL treated with the selective Brutonâ€™s tyrosine kinase inhibitor ONO/GS-4059. <i>Blood</i> , 2017, 129, 2808-2810.	0.6	48
20	Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2012, 158, 589-599.	1.2	45
21	The Novel Nuclear Factor-ÎB Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine. <i>Clinical Cancer Research</i> , 2008, 14, 8102-8111.	3.2	44
22	Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. <i>Leukemia</i> , 2015, 29, 2411-2414.	3.3	42
23	Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. <i>Leukemia</i> , 2012, 26, 826-830.	3.3	39
24	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 152, 570-578.	1.2	38
25	The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-ÎB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. <i>Oncotarget</i> , 2012, 3, 525-534.	0.8	38
26	Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 3607-3617.	0.6	31
27	Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 123-131.	0.8	31
28	Guideline for the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 344-359.	1.2	29
29	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. <i>Blood</i> , 2016, 128, 563-573.	0.6	27
30	Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. <i>Leukemia</i> , 2017, 31, 2085-2093.	3.3	27
31	South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients. <i>British Journal of Haematology</i> , 2008, 142, 606-609.	1.2	26
32	Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. <i>Cell Proliferation</i> , 2011, 44, 380-390.	2.4	26
33	Telomere length is a critical determinant for survival in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 94-98.	1.2	26
34	A multi-centre phase I trial of the <sc>PARP</sc> inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-lymphocytic leukaemia or mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 429-433.	1.2	23
35	Leukemic and Non-Leukemic Lymphocytes from Patients with Li Fraumeni Syndrome Demonstrate Loss of p53 Function, Bcl-2 Family Dysregulation and Intrinsic Resistance to Conventional Chemotherapeutic Drugs But Not Flavopiridol. <i>Cell Cycle</i> , 2003, 2, 52-57.	1.3	21
36	Telomere length is an independent prognostic marker in <sc>MDS</sc> but not in <i>de novo</i> <sc>AML</sc>. <i>British Journal of Haematology</i> , 2017, 178, 240-249.	1.2	21

#	ARTICLE	IF	CITATIONS
37	Understanding cancer cell survival is key to patient survival. <i>Lancet Oncology</i> , The, 2015, 16, 122-124.	5.1	20
38	Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3K $\gamma$ inhibition. <i>Leukemia</i> , 2015, 29, 744-747.	3.3	20
39	Increased frequency of CD4 <sup>+</sup> PD-1 <sup>+</sup> HLA-DR <sup>+</sup> T cells is associated with disease progression in CLL. <i>British Journal of Haematology</i> , 2020, 188, 872-880.	1.2	18
40	Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF- $\kappa$ B Inhibitory Capacity of Pyrrolbenzodiazepines (PBDs). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2127-2139.	2.9	17
41	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton <sup>TM</sup> s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , 2020, 34, 1458-1461.	3.3	15
42	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 776-781.	2.0	14
43	Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor. <i>Oncotarget</i> , 2017, 8, 11414-11424.	0.8	14
44	Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. <i>British Journal of Haematology</i> , 2017, 176, 573-582.	1.2	13
45	A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-Idel). <i>British Journal of Haematology</i> , 2021, 194, 69-77.	1.2	13
46	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	3.3	13
47	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. <i>Blood</i> , 2020, 136, 17-18.	0.6	11
48	NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.. <i>Blood</i> , 2007, 110, 752-752.	0.6	11
49	Telomere fusions associate with coding sequence and copy number alterations in CLL. <i>Leukemia</i> , 2019, 33, 2093-2097.	3.3	9
50	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 665.	5.8	9
51	All trans retinoic acid enhances human LAK activity. <i>European Journal of Haematology</i> , 1995, 54, 95-100.	1.1	8
52	Apoptosis Deregulation in CLL. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 151-171.	0.8	8
53	Mechanically Ventilated Patients Shed High-Titer Live Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for Extended Periods From Both the Upper and Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2022, 75, e82-e88.	2.9	8
54	The Bruton <sup>TM</sup> s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL). <i>Blood</i> , 2014, 124, 3328-3328.	0.6	7

#	ARTICLE	IF	CITATIONS
55	In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1995, 16, 277-81.	1.3	7
56	A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. Oncotarget, 2015, 6, 32669-32680.	0.8	6
57	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. Journal of Clinical Oncology, 2018, 36, TPS7588-TPS7588.	0.8	6
58	Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. Cancers, 2022, 14, 1600.	1.7	6
59	Targeting the Non-Canonical NF- $\kappa$ B Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma. Cancers, 2022, 14, 1489.	1.7	6
60	Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Therapeutic Endpoint for Relapsed CLL.. Blood, 2007, 110, 3114-3114.	0.6	5
61	The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.. Journal of Clinical Oncology, 2014, 32, 8553-8553.	0.8	5
62	Clinical utility of telomere length measurements in cancer. Current Opinion in Genetics and Development, 2020, 60, 107-111.	1.5	4
63	Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. Haematologica, 2020, 105, 2868-2871.	1.7	2
64	Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38+ Sub-Clones When Compared with CD38 <sup>+</sup> Sub-Clones Derived from the Same CLL Patient.. Blood, 2005, 106, 180-180.	0.6	2
65	Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3233-3233.	0.6	2
66	PRELIMINARY RESULTS OF A PHASE 1B STUDY OF TIRABRUTINIB (GS-4059/ONO-4059) IN COMBINATION WITH ENTOSPLETINIB IN PATIENTS WITH B-CELL MALIGNANCIES. Hematological Oncology, 2017, 35, 266-266.	0.8	1
67	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia. Blood, 2018, 132, 3135-3135.	0.6	1
68	Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Icicle Extension Study. Blood, 2016, 128, 2049-2049.	0.6	1
69	Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies. Blood, 2016, 128, 2961-2961.	0.6	1
70	BAX UTR G (-248) A Polymorphism Has No Impact on Survival in Patients with Multiple Myeloma.. Blood, 2006, 108, 5022-5022.	0.6	1
71	In Vitro Co-Culture of CLL-B Cells Reveals Long-Term Survival, Proliferation, and Maintenance of Telomere Length. Blood, 2016, 128, 350-350.	0.6	1
72	Is venetoclax a new wonder drug in CLL?. British Journal of Haematology, 2019, 185, 643-646.	1.2	0

#	ARTICLE	IF	CITATIONS
73	ZAP-70 Expression Is More Predictive Than VH Gene Mutational Status of BCR-Mediated Tyrosine Phosphorylation, NF- $\kappa$ B Activation and CLL Cell Survival.. Blood, 2005, 106, 2942-2942.	0.6	0
74	The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.. Blood, 2005, 106, 2981-2981.	0.6	0
75	Constitutive Nuclear p65 NF- $\kappa$ B Expression Predicts for Spontaneous Apoptosis and In Vitro Sensitivity to Fludarabine in CLL Cells.. Blood, 2006, 108, 4974-4974.	0.6	0
76	Integrating Prognostic Markers and Cellular Signaling Identifies More Chronic Lymphocytic Leukemia Patients with Adverse Prognosis.. Blood, 2006, 108, 2782-2782.	0.6	0
77	Pharmacological Inhibition of NF- $\kappa$ B Underpins the Strong Synergy Between LC-1 and Fludarabine in Chronic Lymphocytic Leukaemia Cells. Blood, 2008, 112, 380-380.	0.6	0
78	Rel a Is a Novel Prognostic Marker in CLL That Is Independent of VH Gene Mutation Status, CD38 Expression and ZAP-70 Expression. Blood, 2008, 112, 4153-4153.	0.6	0
79	CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161. Blood, 2014, 124, 3293-3293.	0.6	0
80	Genetic Analysis of Distinct Phenotypic Subsets within MM1.S Multiple Myeloma Cell Line Reveals the Pre-Existence of MM.1R-like Glucocorticoid Resistance and a Sub-Clone with an Activating PI3-Kinase Delta Mutation That Is Preferentially Sensitive to the Selective PI3-Kinase Inhibitor, Idelalisib. Blood, 2016, 128, 4449-4449.	0.6	0
81	Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies.. Journal of Clinical Oncology, 2017, 35, 7518-7518.	0.8	0
82	Development and Characterisation of an in Vitro Model of Multiple Myeloma. Blood, 2018, 132, 4505-4505.	0.6	0
83	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma. Blood, 2018, 132, 5344-5344.	0.6	0
84	Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens. Blood, 2020, 136, 46-47.	0.6	0